Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

(2009) Stefan James et al.   AMERICAN HEART JOURNAL

Recent developments in clopidogrel pharmacology and their relation to clinical outcomes

(2009) Paul A Gurbel et al.   Expert Opinion on Drug Metabolism & Toxicology

Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction

(2009) Paul A. Gurbel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ticagrelor binds to human P2Y12independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation

(2009) J. J. J. VAN GIEZEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiplatelet Drugs

(2008) Carlo Patrono et al.   CHEST